Zeo Scientifix, INC 8-K filings

Zeo ScientifiX announces the launch of ZEO Xperience, a three-day educational event for healthcare professionals focused on regenerative biologics.

ZEO ScientifiX announces strategic initiatives to enhance regenerative medicine research, physician education, and scientific collaboration within Florida's growing life sciences sector.

Zeo ScientifiX announced significant year-over-year revenue growth of 124.6% for the quarter and 79.9% for the six months ended April 30, 2026, driven by its regenerative biologics portfolio.

Zeo ScientifiX will host a virtual educational webinar for healthcare professionals on July 22, 2026, focusing on the advancements and regulatory landscape of regenerative medicine in the Southeast.

Zeo ScientifiX announced its Medical Advisory Board member, Dr. Constantino Mendieta, utilized donated products during a humanitarian mission in Peru to treat child burn victims.

Zeo ScientifiX, Inc. has granted a total of 3,890,000 stock options to key executives, consultants, and directors under its 2021 Incentive Stock Plan.

Zeo ScientifiX announced the expansion of its Medical Advisory Board with nine new physicians and scientific innovators in regenerative and longevity medicine.

ZEO ScientifiX announces the formal launch of its Physician-Led Patient Masterclass program to educate patients on regenerative medicine.

ZEO ScientifiX announced unaudited monthly sales exceeded $1 million for the first time in April 2026, marking a significant growth inflection point.

Zeo ScientifiX announces a significant milestone, having successfully trained over 500 clinicians through its monthly Masterclass series focused on regenerative biologics treatments.

ZEO ScientifiX announces a strategic collaboration with Regen Therapy to supply advanced biologic therapeutics for regenerative medicine offerings.

Zeo ScientifiX has been selected as a Qualified Team in the $101 million XPRIZE Healthspan competition to develop therapeutics that reverse aging by up to 20 years.

ZEO ScientifiX announced its role as the official educational partner for regenerative medicine with the American Academy of Anti-Aging Medicine (A4M) at Longevity SpringFest 2026.

ZEO ScientifiX, Inc. announced the termination of Dr. John D. Kisiday, Ph.D. as its Chief Science Officer, effective March 23, 2026.

Zeo ScientifiX, Inc. announced the appointment of Dr. John D. Kisiday, Ph.D., a veteran in tissue engineering and regenerative medicine, as its new Chief Science Officer.

Zeo ScientifiX, Inc. announced the award of 175,000 restricted shares each to its CEO/CFO and CMO under its 2021 Incentive Stock Plan.

Zeo ScientifiX, Cytora Therapeutics, and Made Scientific announce a strategic partnership to advance and commercialize Cytora's novel allogeneic oral mucosal stem cell therapy in the U.S.

ZEO ScientifiX, Inc. announced the appointment of Ian T. Bothwell as its full-time Chief Executive Officer, while he continues to serve as Chief Financial Officer.

ZEO ScientifiX, Inc. announced the termination of Ron Borsheim as its Chief Sales Officer Aesthetics, effective November 30, 2025.

ZEO ScientifiX announces readiness to capitalize on Florida's new stem cell law, SB 1768, expecting significant market expansion and clinical research acceleration.

Zeo ScientifiX, Inc. announced a private placement of 250,000 common shares to a single accredited investor for an aggregate of $1,000,000, payable in ten equal monthly installments.

Zeo ScientifiX, Inc. announced the resignation of Dr. Peter A. M. Everts, Ph.D. as its Chief Scientific and Technology Officer, effective August 1, 2025.

ZEO ScientifiX announces a strategic expansion, including a new website and agency partnerships, to meet anticipated demand in Florida's newly opened stem cell therapy market.

ZEO ScientifiX announced a physician-led Masterclass to educate Florida doctors on the upcoming SB-1768 law, which will allow non-FDA-approved stem cell therapies under strict compliance protocols starting July 1, 2025.

Zeo ScientifiX, Inc. announces the issuance of common stock and warrants to a consultant, and stock options to executives and non-executive directors.

Zeo ScientifiX, Inc. appoints Ron Borsheim as Chief Sales Officer Aesthetics, effective April 1, 2025, with a base salary of $225,000 and stock options.

ZEO ScientifiX, a clinical-stage biopharmaceutical company, has appointed Dr. Peter Everts as its new Chief Scientific and Technology Officer to strengthen its leadership team.

ZEO ScientifiX reports successful completion of Phase I clinical trials for Zofin and growth in sales of its PPX product, positioning the company for continued success in 2025.

Zeo ScientifiX, Inc. announces a joint venture with BioXtek, LLC and the appointment of Dr. Peter A. M. Everts as Chief Scientific and Technology Officer.

Zeo ScientifiX has amended the terms of its Series C Preferred Stock, allowing for easier transfer of shares and modifying the conditions for redemption.